Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. (March 2021)
- Record Type:
- Journal Article
- Title:
- Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. (March 2021)
- Main Title:
- Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma
- Authors:
- Auer, Timo A
Jonczyk, Martin
Collettini, Federico
Marth, Adrian
Wieners, Gero
Hamm, Bernd
Gebauer, Bernhard - Abstract:
- Background: To date there is no therapy consensus in patients with multifocal hepatocellular carcinoma (mHCC). Purpose: To compare outcome of trans-arterial chemoembolization (TACE) with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in mHCC. Material and Methods: In this single-center study, 36 patients without portal vein invasion, treated between May 2014 and May 2018, were enrolled retrospectively. Eighteen consecutive patients received DSM-TACE and were matched by age, gender, BCLC stage, Child-Pugh status, and tumor volume and 18 patients underwent SIRT. Overall survival (OS), progression-free survival (PFS), and local tumor control (LTC) were evaluated. Toxicity profiles for both therapies were also evaluated and compared. Results: In the entire collective, median OS was 9.5, PFS 5.0, and LTC 5.5 months. Subgroup analysis revealed an OS of 9.5 months in both groups ( P = 0.621). PFS was 6 months for the SIRT and 4 months for the DSM-TACE cohort ( P = 0.065). Although not significantly, LTC was lower (4 months) in the SIRT compared to the DSM-TACE cohort (7 months; P = 0.391). When DSM-TACE was performed ≥3 times (n = 11), OS increased, however without statistical difference compared to SIRT, to 11 months, PFS to 7 months, and LTC to 7 months. When DSM-TACE was performed <3 times (n = 7), OS, PFS, and LTC decreased (5 months, P = 0.333; 2 months, P = 0.047; 2 months, P = 0.47). Toxicity profiles and adverse eventBackground: To date there is no therapy consensus in patients with multifocal hepatocellular carcinoma (mHCC). Purpose: To compare outcome of trans-arterial chemoembolization (TACE) with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in mHCC. Material and Methods: In this single-center study, 36 patients without portal vein invasion, treated between May 2014 and May 2018, were enrolled retrospectively. Eighteen consecutive patients received DSM-TACE and were matched by age, gender, BCLC stage, Child-Pugh status, and tumor volume and 18 patients underwent SIRT. Overall survival (OS), progression-free survival (PFS), and local tumor control (LTC) were evaluated. Toxicity profiles for both therapies were also evaluated and compared. Results: In the entire collective, median OS was 9.5, PFS 5.0, and LTC 5.5 months. Subgroup analysis revealed an OS of 9.5 months in both groups ( P = 0.621). PFS was 6 months for the SIRT and 4 months for the DSM-TACE cohort ( P = 0.065). Although not significantly, LTC was lower (4 months) in the SIRT compared to the DSM-TACE cohort (7 months; P = 0.391). When DSM-TACE was performed ≥3 times (n = 11), OS increased, however without statistical difference compared to SIRT, to 11 months, PFS to 7 months, and LTC to 7 months. When DSM-TACE was performed <3 times (n = 7), OS, PFS, and LTC decreased (5 months, P = 0.333; 2 months, P = 0.047; 2 months, P = 0.47). Toxicity profiles and adverse event analysis only revealed a significant difference for nausea and vomiting (more frequent in the SIRT cohort, P = 0.015), while no other parameter showed a significant difference ( P > 0.05). Conclusion: DSM-TACE might be an alternative to SIRT in multifocal HCC patients as OS, PFS, and LTC did not differ significantly and toxicity profiles seem to be comparable. … (more)
- Is Part Of:
- Acta radiologica. Volume 62:Number 3(2021)
- Journal:
- Acta radiologica
- Issue:
- Volume 62:Number 3(2021)
- Issue Display:
- Volume 62, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 62
- Issue:
- 3
- Issue Sort Value:
- 2021-0062-0003-0000
- Page Start:
- 313
- Page End:
- 321
- Publication Date:
- 2021-03
- Subjects:
- Hepatocellular carcinoma -- trans-arterial chemoembolization -- degradable starch microspheres -- selective internal radiation therapy -- multifocal hepatocellular carcinoma
Radiology, Medical -- Periodicals
Radiography, Medical -- Periodicals
Radiotherapy -- Periodicals
616.0757 - Journal URLs:
- http://acr.sagepub.com ↗
http://ar.rsmjournals.com ↗
http://www.uk.sagepub.com/home.nav ↗
http://informahealthcare.com/loi/ard ↗
http://www.tandf.co.uk/journals/titles/02841851.asp ↗ - DOI:
- 10.1177/0284185120926474 ↗
- Languages:
- English
- ISSNs:
- 0284-1851
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0662.000000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15113.xml